Seres Therapeutics (MCRB) Shares are Down -8.28%

Seres Therapeutics (MCRB) has risen sharply, recording gains of 21.32% in the past 4 weeks. However, the stock has corrected -8.28% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 21.98% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.12% and the 50-Day Moving Average is 12.49%.The 200 Day SMA reached 51.2%


Seres Therapeutics (NASDAQ:MCRB): The stock opened in the green at $12.75 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $12.7757 and a low of $12 for the day. The stock did not find buyers even at the lows and closed at $12.29 recording a loss of -3.08%. 557,294 shares exchanged hands during the trading day. The stock had closed at $12.29 in the previous days trading.

Seres Therapeutics (MCRB) : The highest level Seres Therapeutics (MCRB) is projected to reach is $23 for the short term and the lowest estimate is at $12. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $15.5 and the possibility the share price can swing is $5.2.

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. Its SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.